Relationship between efficacy of sunitinib and KIT mutation of patients with advanced gastrointestinal stromal tumors after failure of imatinib: A systematic review

BACKGROUND: A large number of studies have shown that KIT mutations are closely related to the prognosis of gastrointestinal stromal tumors (GISTs). At the same time, sunitinib (SU) has become the second-line recommended drug for GISTs because of its efficacy. We initiated a systematic review to com...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Fuming, Xiao, Weidong, Jiang, Yahui, Xia, Xiao, Wang, Yaxu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531104/
https://www.ncbi.nlm.nih.gov/pubmed/31083182
http://dx.doi.org/10.1097/MD.0000000000015478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531104/
https://www.ncbi.nlm.nih.gov/pubmed/31083182
http://dx.doi.org/10.1097/MD.0000000000015478

Ejemplares similares